

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:15:02 ON 09 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:15:16 ON 09 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2007 HIGHEST RN 920112-67-0

DICTIONARY FILE UPDATES: 8 FEB 2007 HIGHEST RN 920112-67-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen


ENTER SCREEN EXPRESSION OR (END):end

=> screen 1006

L1 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10560764.str



```

chain nodes :
7  8  9 10 11 12 13 20 21 22 23 24 25 26 27
ring nodes :
1  2  3  4  5  6 14 15 16 17 18 19
chain bonds :
6-7 7-8 8-9 9-10 10-11 10-13 11-12 12-14 17-20 20-21 21-22 21-25 22-23
22-24 25-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
9-10 10-13 12-14 21-25 22-23 22-24
exact bonds :
6-7 7-8 8-9 10-11 11-12 17-20 20-21 21-22 25-26 26-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:Atom

```

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> d L1


L1 HAS NO ANSWERS

L1 SCR 1006

=> d L2

L2 HAS NO ANSWERS

L2 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L2 full
FULL SEARCH INITIATED 14:15:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 716 TO ITERATE

100.0% PROCESSED 716 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

L4 19 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 14:16:03 ON 09 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2007 VOL 146 ISS 8
FILE LAST UPDATED: 8 Feb 2007 (20070208/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L4
L5 9 L4



=> d L5 1-9 bib abs

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:61504 CAPLUS
DN 146:142376
TI Preparation of phenylpropionic acid derivatives and pharmaceutical compositions thereof
IN Bjoerk, Seth
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 57pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008156	A1	20070118	WO 2006-SE864	20060710
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,			

US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI SE 2005-1644 A 20050711
 GI



AB The title phenylpropionic acid derivs. I [wherein n = 1-2; R1 = H, Cl, CF3, or OCF3; R2 = H or F; R3 = alkyl] or tert-butylamine salts thereof were prepared as PPAR active compds. for treatment of metabolic syndrome including type 2 diabetes mellitus (no data). For example, II and II•tert-butylamine were prepared in a multi-step synthesis. Pharmaceutical compns. were described.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:605020 CAPLUS

DN 145:83115

TI Preparation of tris(hydroxymethyl)methylamine and ethanolamine salts of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]}-2-oxoethoxy)phenyl)propanoic acid for treating lipid disorders

IN Booth, Rebecca J.; Dahlstroem, Mikael

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065214	A1	20060622	WO 2005-SE1916	20051214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
PRAI SE 2004-3072 A 20041216
GI



AB The invention relates to a compound selected from one or more of the following: a tris(hydroxymethyl)methylamine salt or an ethanolamine salt of title compound I or a pharmaceutical composition comprising the compound
Thus I was prepared in 4 steps from Et (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate, benzyl bromoacetate, and N-hexyl-2-phenylethylamine. X-ray powder diffraction patterns for bot salts of I are given. Both salts have an EC50 of less than 0.5 $\mu\text{mol/l}$ for PPAR α .

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1335635 CAPLUS

DN 144:69628

TI Preparation of phenoxyacetamide derivatives as modulators of peroxisome proliferator-activated receptors (PPAR)

IN Alstermark, Eva-Lotte Lindstedt; Olsson, Anna Christina; Li, Lanna
PA Swed.

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 499,261.
CODEN: USXXCO


DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005282822	A1	20051222	US 2004-26806	20041230
	WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	WO 2003051822	A1	20030626	WO 2002-GB5744	20021218
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	CN 1896045	A	20070117	CN 2006-10007173	20021218
	WO 2004056748	A1	20040708	WO 2003-GB5602	20031219
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,	

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2004113270 A2 20041229 WO 2004-EP6597 20040617
 WO 2004113270 A3 20050331
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 EP 1676833 A1 20060705 EP 2006-5766 20040617
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2005336209 A 20051208 JP 2005-235794 20050816
 JP 2006045240 A 20060216 JP 2005-253346 20050901
 JP 2006298924 A 20061102 JP 2006-123399 20060427
 JP 2006298925 A 20061102 JP 2006-139673 20060519
 PRAI SE 2001-4334 A 20011219
 WO 2002-GB5738 W 20021218
 WO 2002-GB5744 A 20021218
 GB 2002-29931 A 20021221
 GB 2003-14079 A 20030618
 WO 2003-GB305602 A 20031219
 WO 2004-EP6597 A 20040617
 US 2005-499261 A2 20050304
 CN 2002-828123 A3 20021218
 JP 2003-552709 A3 20021218
 JP 2003-552710 A3 20021218
 JP 2004-561668 A3 20031219
 EP 2004-740044 A3 20040617
 JP 2006-515989 A3 20040617
 OS MARPAT 144:69628
 GI



AB The phenyl-, phenoxy-, or phenylthioalkanamidetitle compds., (in particular phenoxyacetamide derivs.) (I) [A is situated in the ortho, meta or para position and represents CR₃R₄CR₁R₂COR, CR₃:CR₁COR (wherein R = H, alkyl, (un)substituted HO or NH₂; R₁ = alkyl, aryl, alkenyl, alkynyl, or when A is CR₃R₄CR₁R₂COR, R₁ can also be cyano, (un)substituted HO, SH, OCONH₂, SO₂NH₂, CO₂H, etc.; R₂ = H, halogen, alkyl, aryl, alkylaryl; R₃, R₄ = H, alkyl, aryl, alkylaryl); Y = O, S, a single bond; n = an integer of 1-4; X = alkyl; R₅, R₆ = H, each (un)substituted C₁-13 alkyl, C₂-10 alkenyl, or C₂-10 alkynyl; or R₅, R₆ = each (un)substituted C₃-8

cycloalkyl, C3-C8 cycloalkenyl, aryl, heterocyclyl, or heteroaryl; or R5 and R6 together with the nitrogen atom to which they are attached form a single or a fused heterocyclic system] are prepared. These compds. are useful in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, and other manifestations of the metabolic syndrome. Thus, a solution of 0.598 g N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine and 0.593 g [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid in 20 mL CH₂Cl₂ was treated with 0.80 mL N,N-diisopropylethylamine and 0.674 g O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and the reaction mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., 74% Et (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoate (II). A solution of 0.748 g II in 70 mL MeCN was treated with 35 mL 0.10 M LiOH and the reaction mixture was stirred at room temperature overnight, neutralized with 5% HCl, concentrated, acidified with 5% HCl, and extracted

with



EtOAc to give 97% (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid (III). III showed EC₅₀ of 0.001 µmol/L for human PPAR α .

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1154649 CAPLUS
 DN 142:93514
 TI Preparation of phenylpropanoic acid derivatives as PPAR α agonists
 IN Li, Lanna; Lindstedt-Alstermark, Eva-Lotte; Olsson, Christina
 PA Astrazeneca Ab, Swed.
 SO PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004113270	A2	20041229	WO 2004-EP6597	20040617
	WO 2004113270	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004249409	A1	20041229	AU 2004-249409	20040617
	CA 2528234	A1	20041229	CA 2004-2528234	20040617
	US 2005148656	A1	20050707	US 2003-518777	20040617
	EP 1675820	A2	20060705	EP 2004-740044	20040617
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	EP 1676833	A1	20060705	EP 2006-5766	20040617
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004011484	A	20060725	BR 2004-11484	20040617
	CN 1835913	A	20060920	CN 2004-80023304	20040617
	JP 2006527730	T	20061207	JP 2006-515989	20040617
	US 2005282822	A1	20051222	US 2004-26806	20041230
	NO 2005005892	A	20060106	NO 2005-5892	20051212
	JP 2006298925	A	20061102	JP 2006-139673	20060519
	US 2006258866	A1	20061116	US 2006-477168	20060628
PRAI	GB 2003-14079	A	20030618		
	SE 2001-4334	A	20011219		

WO 2002-GB5738	W	20021218
WO 2002-GB5744	A	20021218
GB 2002-29931	A	20021221
WO 2003-GB305602	A	20031219
EP 2004-740044	A3	20040617
JP 2006-515989	A3	20040617
WO 2004-EP6597	W	20040617
US 2005-518777	A3	20050303
US 2005-499261	A2	20050304

OS MARPAT 142:93514
GI



AB Title compds. represented by the formula I [wherein A = CR₃(R₄)CR₁(R₂)COR or C(R₃):C(R₁)COR; R = H, alkoxy, (alkyl)aryloxy, amino, etc.; R₁ = alkyl, aryl, alkenyl, alkynyl, etc.; R₂ = H, halo, alkyl, (alkyl)aryl; R₃, R₄ = independently H, alkyl, (alkyl)aryl; T = O, S or a single bond; n = 1-4; R₅, R₆ = independently selected substituent comprising C, H, N, O, S, Se, P or halo; with provisos; optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof] were prepared as PPAR α agonists. For example, II was given in a multi-step synthesis starting from the reaction of 2,4-difluorobenzylamine with octanoic acid. I had EC₅₀ values of less than 0.1 μ mol/L for PPAR α and showed the ration of the EC₅₀(PPAR γ) with EC₅₀(PPAR α) is greater than 150:1. Thus, I and their pharmaceutical compns. are useful for the treatment of clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance (no data).

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1127321 CAPLUS

DN 142:49239

TI Pharmaceutically useful salts (2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid, preparation thereof, and therapeutic use

IN Ragnar, Ralf; Stahle, Erica

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110985	A1	20041223	WO 2004-SE965	20040616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004247611 A1 20041223 AU 2004-247611 20040616
 CA 2527608 A1 20041223 CA 2004-2527608 20040616
 EP 1638921 A1 20060329 EP 2004-736956 20040616

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004011455 A 20060718 BR 2004-11455 20040616
 CN 1805922 A 20060719 CN 2004-80016838 20040616
 JP 3836498 B2 20061025 JP 2006-517040 20040616
 JP 2006527767 T 20061207
 US 2006194879 A1 20060831 US 2005-560127 20051209
 NO 2005005923 A 20060106 NO 2005-5923 20051213

PRAI GB 2003-14136 A 20030618
 WO 2004-SE965 W 20040616

AB The invention discloses a calcium or magnesium salt of (2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid. Compds. of the invention (preparation included) may be used to treat e.g. dyslipidemia and type 2 diabetes.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1127320 CAPLUS
 DN 142:49238
 TI Pharmaceutically useful salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid, their preparation, and their therapeutic use
 IN Aurell, Carl-Johan; Dahlstroem, Mikael; Lindstedt-Alstermark, Eva-Lotte; Minidis, Anna; Ohlsson, Bengt; Stahle, Erica
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110984	A1	20041223	WO 2004-SE964	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004247610	A1	20041223	AU 2004-247610	20040616
CA 2528932	A1	20041223	CA 2004-2528932	20040616
EP 1638922	A1	20060329	EP 2004-749009	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1809529	A	20060726	CN 2004-80016948	20040616


BR 2004011525	A	20060801	BR 2004-11525	20040616
JP 3822900	B2	20060920	JP 2006-517039	20040616
JP 2006527766	T	20061207		
NO 2005005922	A	20060106	NO 2005-5922	20051213
US 2006142389	A1	20060629	US 2005-560657	20051213
PRAI GB 2003-14129	A	20030618		
WO 2004-SE964	W	20040616		

AB The invention discloses salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid e.g. the L-arginine salt. Preparation of compds. of the invention is described. The compds. of the invention are useful in the treatment of e.g. dyslipidemias and other manifestations of the metabolic syndrome.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1127318 CAPLUS
DN 142:56001
TI Preparation of (2S)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives
IN Aurell, Carl-Johan; Macedo, Emmanuel; Minidis, Anna; Yousefi-Salakdeh, Esmail
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110982	A1	20041223	WO 2004-SE966	20040616
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004247612	A1	20041223	AU 2004-247612	20040616
	CA 2528933	A1	20041223	CA 2004-2528933	20040616
	EP 1638920	A1	20060329	EP 2004-736958	20040616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1809528	A	20060726	CN 2004-80017131	20040616
	BR 2004011558	A	20060801	BR 2004-11558	20040616
	JP 3822901	B2	20060920	JP 2006-517041	20040616
	JP 2006527768	T	20061207		
	NO 2005005924	A	20060105	NO 2005-5924	20051213
	US 2006142392	A1	20060629	US 2005-560764	20051213
PRAI	GB 2003-14134	A	20030618		
	WO 2004-SE966	W	20040616		
OS	MARPAT 142:56001				
GI					



AB The present invention provides a process for preparation of the title compds. I (R = H, R1 = n-C6H13) by reacting I (R = H, or protecting group, R1 = H) with C6H13X (X = leaving group) in the presence of a base and inert solvent at a temperature in the range -25°C to 150°C and optionally, when OR represents a protecting group, removal of the protecting group.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:2837 CAPLUS

DN 140:59411

TI Preparation of phenoxyalkanamides as amide linker peroxisome proliferator activated receptor agonists for treating and/or preventing diabetes mellitus and syndrome X

IN Ferritto Crespo, Rafael; Martin, Jose Alfredo; Martin-Ortega, Finger Maria Dolores; Rojo Garcia, Isabel; Shen, Quanrong; Warshawsky, Alan M.; Xu, Yanping

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 168 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000789	A1	20031231	WO 2003-US16207	20030611
	WO 2004000789	A9	20040311		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2488972	A1	20031231	CA 2003-2488972	20030611
	AU 2003241579	A1	20040106	AU 2003-241579	20030611
	EP 1517882	A1	20050330	EP 2003-731326	20030611
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003011834	A	20050412	BR 2003-11834	20030611
	CN 1662487	A	20050831	CN 2003-814173	20030611
	JP 2005529975	T	20051006	JP 2004-515700	20030611
	US 2006111406	A1	20060525	US 2004-517581	20041208
PRAI	US 2002-390102P	P	20020619		
	WO 2003-US16207	W	20030611		
OS	MARPAT 140:59411				
GI					



AB The present invention is directed to phenoxyalkanamides (shown as I; variables defined below; e.g. II), compns., and their use as peroxisome proliferator activated receptor agonists for treating and/or preventing diabetes mellitus and syndrome X. The binding and cotransfection efficacy values found for compds. of this invention that are useful for modulating a PPAR α receptor are about <100 nM and >50%, resp. Although the methods of preparation are not claimed, .apprx.140 example prepsns. of I are included. For example, II was prepared in 3 steps starting from (2S)-2-ethoxy-3-(4-hydroxyphenyl)propionic acid Me ester, (2S)-2-hydroxypropionic acid benzyl ester and involving intermediates (2S)-3-[4-[[[(1R)-1-[(benzyloxy)carbonyl]ethyl]oxy]phenyl]-2-ethoxypropionic acid Et ester and (2S)-3-[4-[[[(1R)-1-carboxyethyl]oxy]phenyl]-2-ethoxypropionic acid. For I: R1 = H, C1-C8 alkyl, C3-C6 cycloalkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, aminoC1-C4alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, arylheteroC1-C8alkyl, -CHC(O)C1-C4 alkoxy, C0-4-alkyl-C(O)heteroC1-C8alkyl, and -CH2C(O)-R15R16. R2 = C1-C8 alkyl, C3-C6 cycloalkyl, aryl-C0-C4-alkyl, heteroaryl-C0-C4-alkyl, heteroC1-C6cycloalkylaryl, heteroC1-C6cycloalkylarylC1-C4alkyl, aminoC1-C4alkyl, C3-C6 cycloalkylaryl-C0-C2-alkyl, arylheteroC1-C8alkyl, C0-C4-alkyl-C(O)heteroC1-C8alkyl, -CH(C(O)OCH3)benzyl, and -CH2C(O)R15''R16''. R1 and R2 together may form a heterocyclic ring which heterocyclic ring is (un)substituted with 1-3 substituents R1' and which heterocyclic ring is optionally fused with an aryl; E = C(R3)(R4)A, (CH2)nCOOR13, aryl-C0-C4-alkyl, thio-C1-C4-alkyl, thioaryl, arylC1-C4alkoxy, C1-C4alkoxy C1-C4alkyl, aminoaryl, and aminoC1-C4alkyl. R5 and R6 = H, C1-C8 alkyl, aryl-C0-C4-alkyl, heteroaryl-C0-C4-alkyl, C3-C6 cycloalkyl, aryl-C0-C2-alkyl, C3-C6 cycloalkyl-C0-2-alkyl, and -CH2C(O)R17R18.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:491168 CAPLUS
DN 139:69049
TI Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
IN Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2470491	A1	20030626	CA 2002-2470491	20021218
AU 2002366315	A1	20030630	AU 2002-366315	20021218
EP 1458673	A1	20040922	EP 2002-804964	20021218
EP 1458673	B1	20060906		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002014988	A	20041214	BR 2002-14988	20021218
HU 200402133	A2	20050228	HU 2004-2133	20021218
CN 1620422	A	20050525	CN 2002-828123	20021218
CN 1620423	A	20050525	CN 2002-828155	20021218
US 2005171204	A1	20050804	US 2003-499261	20021218
JP 2005526011	T	20050902	JP 2003-552709	20021218
JP 3784804	B2	20060614		
TW 253444	B	20060421	TW 2002-91136518	20021218
NZ 533276	A	20060428	NZ 2002-533276	20021218
TW 255807	B	20060601	TW 2002-91136519	20021218
AT 338743	T	20060915	AT 2002-804964	20021218
CN 1896045	A	20070117	CN 2006-10007173	20021218
ZA 2004004657	A	20050829	ZA 2004-4657	20040611
ZA 2004004658	A	20060222	ZA 2004-4658	20040611
NO 2004003023	A	20040715	NO 2004-3023	20040715
US 2005282822	A1	20051222	US 2004-26806	20041230
JP 2005336209	A	20051208	JP 2005-235794	20050816
JP 2006298924	A	20061102	JP 2006-123399	20060427

PRAI SE 2001-4334	A	20011219		
CN 2002-828123	A3	20021218		
JP 2003-552709	A3	20021218		
JP 2003-552710	A3	20021218		
WO 2002-GB5738	W	20021218		
WO 2002-GB5744	A	20021218		
GB 2002-29931	A	20021221		
GB 2003-14079	A	20030618		
WO 2003-GB305602	A	20031219		
WO 2004-EP6597	A	20040617		
US 2005-499261	A2	20050304		

OS MARPAT 139:69049
 GI



AB The S enantiomer of I, n = 1 or 2, (C₆H₁₃ = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (2S)-2-ethoxy-3-(4-{2-oxo-2-[(2-phenylethyl)amino]ethoxy}phenyl)-propanoic acid
MISSING TERM BEFORE '(2S'
Search expressions cannot begin with operators.

=> s 2-ethoxy-3-(4-{2-oxo-2-[(2-phenylethyl)amino]ethoxy}phenyl)propanoic acid
MISSING OPERATOR '-ETHOXY-3-(4-{2-OXO-2'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s phenethylamino ethoxy phenyl propanoic acid derivatives

838 PHENETHYLAMINO
42317 ETHOXY
343103 PHENYL
414 PHENYLS
343381 PHENYL
(PHENYL OR PHENYLS)
1309164 PH
10070 PHS
1313504 PH
(PH OR PHS)
1566052 PHENYL
(PHENYL OR PH)
8991 PROPANOIC
4311309 ACID
1568117 ACIDS
4812460 ACID
(ACID OR ACIDS)
340439 DERIVATIVES
1134482 DERIVS
1240054 DERIVATIVES
(DERIVATIVES OR DERIVS)

L6 0 PHENETHYLAMINO ETHOXY PHENYL PROPANOIC ACID DERIVATIVES
(PHENETHYLAMINO (W) ETHOXY (W) PHENYL (W) PROPANOIC (W) ACID (W) DERIVATIVES)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.29	213.60
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.02	-7.02

STN INTERNATIONAL LOGOFF AT 14:20:59 ON 09 FEB 2007